NEW YORK (GenomeWeb News) – Takeda Pharmaceutical and Kyoto University today announced a five-year deal focused on the development of new central nervous system-acting drugs for obesity and schizophrenia.
Under the terms of the deal, the university and Takeda will seek to identify new drug targets and biomarkers for the diseases. Medical research aimed at developing new drugs will also be conducted "by utilizing not only findings from basic research and clinical data accumulated at the Graduate School of Medicine and the University Hospital, but also its worldwide networks," the partners said.
Financial and other terms were not disclosed.
In a statement Shigenori Ohkawa, chief scientific officer for Takeda, said that "Through the close partnership on research and development, we expect that we weill be able to create innovative drugs for obesity and schizophrenia where there is a high unmet need for patients."
In November, Takeda and Sage Networks announced a partnership also directed at CNS drugs. Last month, the drug firm, Sanford-Burnham Medical Research Institute and Florida Hospital said they would be using genomic and metabolite profiling as part of an effort aimed at developing new therapies for obesity.